Nkarta (NKTX) Gains from Sales and Divestitures (2023 - 2026)
Nkarta's quarterly Gains from Sales and Divestitures came in at $208240.0 in Q1 2026, down 33.35% year-on-year from $312415.0 in Q1 2025, and down 36.37% quarter-over-quarter from $327242.0 in Q4 2025.
Nkarta has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $208240.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 33.35% year-over-year to $208240.0; the trailing twelve-month figure through Mar 2026 stood at $208240.0 (down 33.35% YoY), and the FY2025 full-year result was $327242.0, up 97.53% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $208240.0, down from $327242.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $327242.0 in Q2 2025, with the low at $50469.0 in Q1 2023.
- Average Gains from Sales and Divestitures over 4 years is $186851.9, with a median of $165667.0 recorded in 2024.
- Year-over-year, Gains from Sales and Divestitures surged 164.71% in 2024 and slumped 33.35% in 2026.
- Tracing NKTX's Gains from Sales and Divestitures over 4 years: stood at $88543.0 in 2023, then jumped by 87.1% to $165667.0 in 2024, then jumped by 97.53% to $327242.0 in 2025, then sank by 36.37% to $208240.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $208240.0 (Q1 2026), $327242.0 (Q4 2025), and $327242.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 208,240.00 |
| Mar 31, 2026 | 208,240.00 |
| Dec 31, 2025 | 327,242.00 |
| Dec 31, 2025 | 327,242.00 |
| Sep 30, 2025 | 327,242.00 |
| Sep 30, 2025 | 327,242.00 |
| Jun 30, 2025 | 327,242.00 |
| Jun 30, 2025 | 327,242.00 |
| Mar 31, 2025 | 312,415.00 |
| Mar 31, 2025 | 312,415.00 |
| Dec 31, 2024 | 165,667.00 |
| Dec 31, 2024 | 165,667.00 |
| Sep 30, 2024 | 165,667.00 |
| Sep 30, 2024 | 165,667.00 |
| Jun 30, 2024 | 155,667.00 |
| Jun 30, 2024 | 155,667.00 |
| Mar 31, 2024 | 133,595.00 |
| Mar 31, 2024 | 133,595.00 |
| Dec 31, 2023 | 88,543.00 |
| Dec 31, 2023 | 88,543.00 |
| Sep 30, 2023 | 88,543.00 |
| Sep 30, 2023 | 88,543.00 |
| Jun 30, 2023 | 78,543.00 |
| Jun 30, 2023 | 78,543.00 |
| Mar 31, 2023 | 50,469.00 |
| Mar 31, 2023 | 50,469.00 |